Bi-specific anti-CD19/CD22 CAR T cell therapy has recently been spotlighted for its promising treatment of refractory diffuse large B cell lymphoma (DLBCL) compared to CD19 CAR T cell infusion, albeit the occurrence of CRS.149. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.